These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 17928736

  • 1. The 5-HT(4) agonists cisapride, mosapride, and CJ-033466, a Novel potent compound, exhibit different human ether-a-go-go-related gene (hERG)-blocking activities.
    Toga T, Kohmura Y, Kawatsu R.
    J Pharmacol Sci; 2007 Oct; 105(2):207-10. PubMed ID: 17928736
    [Abstract] [Full Text] [Related]

  • 2. Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-à-gogo K(+) channel.
    Potet F, Bouyssou T, Escande D, Baró I.
    J Pharmacol Exp Ther; 2001 Dec; 299(3):1007-12. PubMed ID: 11714889
    [Abstract] [Full Text] [Related]

  • 3. The in vitro pharmacology and non-clinical cardiovascular safety studies of a novel 5-HT4 receptor agonist, DSP-6952.
    Tsubouchi T, Kunimatsu T, Tsujimoto S, Kiyoshi A, Katsura Y, Oku S, Chihara K, Mine Y, Yamada T, Shimizu I, Bando K.
    Eur J Pharmacol; 2018 May 05; 826():96-105. PubMed ID: 29501863
    [Abstract] [Full Text] [Related]

  • 4. The in vitro pharmacological profile of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity.
    Smith JA, Beattie DT, Marquess D, Shaw JP, Vickery RG, Humphrey PP.
    Naunyn Schmiedebergs Arch Pharmacol; 2008 Jul 05; 378(1):125-37. PubMed ID: 18415081
    [Abstract] [Full Text] [Related]

  • 5. The in vivo gastrointestinal activity of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity.
    Beattie DT, Armstrong SR, Shaw JP, Marquess D, Sandlund C, Smith JA, Taylor JA, Humphrey PP.
    Naunyn Schmiedebergs Arch Pharmacol; 2008 Jul 05; 378(1):139-47. PubMed ID: 18408918
    [Abstract] [Full Text] [Related]

  • 6. An in vitro investigation of the cardiovascular effects of the 5-HT(4) receptor selective agonists, velusetrag and TD-8954.
    Beattie DT, Higgins DL, Ero MP, Amagasu SM, Vickery RG, Kersey K, Hopkins A, Smith JA.
    Vascul Pharmacol; 2013 Jan 05; 58(1-2):150-6. PubMed ID: 23201772
    [Abstract] [Full Text] [Related]

  • 7. Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37 degrees C: Cisapride versus dofetilide.
    Milnes JT, Witchel HJ, Leaney JL, Leishman DJ, Hancox JC.
    J Pharmacol Toxicol Methods; 2010 Jan 05; 61(2):178-91. PubMed ID: 20172036
    [Abstract] [Full Text] [Related]

  • 8. The cardiovascular safety profile of renzapride, a novel treatment for irritable bowel syndrome.
    Meyers NL, Hickling RI.
    J Int Med Res; 2007 Jan 05; 35(6):848-66. PubMed ID: 18034998
    [Abstract] [Full Text] [Related]

  • 9. A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG.
    Rampe D, Roy ML, Dennis A, Brown AM.
    FEBS Lett; 1997 Nov 03; 417(1):28-32. PubMed ID: 9395068
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effects of 5-HT(4) receptor agonists, cisapride and mosapride citrate on electrocardiogram in anaesthetized rats and guinea-pigs and conscious cats.
    Kii Y, Nakatsuji K, Nose I, Yabuuchi M, Mizuki Y, Ito T.
    Pharmacol Toxicol; 2001 Aug 03; 89(2):96-103. PubMed ID: 11555327
    [Abstract] [Full Text] [Related]

  • 12. Thorough QT/QTc Study Shows That a Novel 5-HT4 Receptor Partial Agonist Minesapride Has No Effect on QT Prolongation.
    Hamatani T, Noda N, Takagaki T, Yodo Y, Kawai H, Kakuyama H, Kaji Y, Fujio Y.
    Clin Pharmacol Drug Dev; 2020 Nov 03; 9(8):938-951. PubMed ID: 32087003
    [Abstract] [Full Text] [Related]

  • 13. Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride.
    Mohammad S, Zhou Z, Gong Q, January CT.
    Am J Physiol; 1997 Nov 03; 273(5):H2534-8. PubMed ID: 9374794
    [Abstract] [Full Text] [Related]

  • 14. Effects of 5-HT4-receptor agonists, cisapride, mosapride citrate, and zacopride, on cardiac action potentials in guinea pig isolated papillary muscles.
    Kii Y, Ito T.
    J Cardiovasc Pharmacol; 1997 May 03; 29(5):670-5. PubMed ID: 9213211
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel.
    Davie C, Pierre-Valentin J, Pollard C, Standen N, Mitcheson J, Alexander P, Thong B.
    J Cardiovasc Electrophysiol; 2004 Nov 03; 15(11):1302-9. PubMed ID: 15574182
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Teratogenicity of the I(Kr)-blocker cisapride: relation to embryonic cardiac arrhythmia.
    Sköld AC, Danielsson C, Linder B, Danielsson BR.
    Reprod Toxicol; 2002 Nov 03; 16(4):333-42. PubMed ID: 12220593
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.